MARCO MARTINEZ: Open Payments
NPI 1922542182 · CHULA VISTA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$893 in 34 payments from 13 companies in 2025. Trend: 2023 $784 · 2024 $1,352 · 2025 $893
Food & beverage: $893
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $238 |
| GlaxoSmithKline, LLC. | 7 | $150 |
| Lilly USA, LLC | 5 | $111 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $87 |
| ABBVIE INC. | 3 | $80 |
| Novo Nordisk Inc | 3 | $75 |
| Philips North America LLC | 1 | $27 |
| Kowa Pharmaceuticals America, Inc. | 1 | $24 |
| Seqirus USA Inc | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
Products named: FARXIGA, TRELEGY ELLIPTA, MOUNJARO, JARDIANCE, AIRSUPRA, Ozempic, LINZESS, Vest Therapy Und.
Industry payments across CA — which companies pay providers there.
